MenB is routinely recommended for these groups:
- People age 10 years and older who have functional or anatomic asplenia (including sickle cell disease)
- People age 10 years and older who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor such as eculizumab (Soliris, Alexion Pharmaceuticals) or ravulizumab (Ultomiris, Alexion Pharmaceuticals)
- People age 10 years and older who are exposed during an outbreak caused by serogroup B
- Microbiologists who work with meningococcal isolates in a laboratory
For adolescents and young adults not otherwise at increased risk for meningococcal B disease, ACIP recommends that a MenB series may be administered to people 16 through 23 years of age (preferred age 16 through 18 years) on the basis of shared clinical decision-making. The shared clinical decision-making recommendation allows the clinician and patient to decide together based upon the risks and benefits of vaccination for the individual patient.